Cibus (NASDAQ:CBUS) Announces Earnings Results

Posted by Stanley Muller on Aug 13th, 2026

Cibus (NASDAQ:CBUS – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.10), FiscalAI reports. The company had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.70 million. Cibus had a negative net margin of 2,366.33% and a negative return on equity of 200.87%.

Here are the key takeaways from Cibus’ conference call:

Revenue increased 35% year to date to $2.7 million, driven by Sustainable Ingredients collaboration agreements, while R&D and SG&A expenses declined by nearly $5 million year over year.
Cibus expects additional scale-up orders for its biofragrance program in the second half of 2026 and estimates a potential $20 million–$40 million annual revenue opportunity when fully commercialized.
The company pushed its expected initial Latin American rice commercialization from late 2027 to 2028; U.S. commercialization remains targeted for 2029, and royalties are not expected to begin until 2028.
Cibus highlighted expanding rice partnerships, including Interoc’s increase from two traits to five, and described a potential rice royalty opportunity exceeding $200 million annually at peak adoption across the Americas.
Cibus had $20.4 million in cash at June 30 and expects funding only into early Q1 2027, while its projected annualized net cash usage exiting 2026 increased to approximately $35 million as it invests in technology and personnel.

Cibus Price Performance

Shares of NASDAQ CBUS traded up $0.01 during mid-day trading on Thursday, hitting $1.90. 240,835 shares of the company’s stock traded hands, compared to its average volume of 455,177. The company’s 50-day moving average is $1.63 and its two-hundred day moving average is $1.97. The company has a market capitalization of $145.03 million, a P/E ratio of -0.96 and a beta of 1.61. Cibus has a 1 year low of $1.09 and a 1 year high of $4.19.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CBUS shares. Weiss Ratings lowered Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Wall Street Zen upgraded Cibus from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cibus presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Read Our Latest Analysis on CBUS

Institutional Investors Weigh In On Cibus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PACK Private Wealth LLC bought a new stake in shares of Cibus in the 4th quarter valued at approximately $27,000. Qube Research & Technologies Ltd purchased a new position in shares of Cibus during the second quarter valued at approximately $39,000. Squarepoint Ops LLC purchased a new stake in shares of Cibus in the third quarter worth approximately $62,000. AQR Capital Management LLC purchased a new stake in Cibus in the first quarter worth $73,000. Finally, Raymond James Financial Inc. lifted its position in shares of Cibus by 31.0% during the second quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock worth $74,000 after purchasing an additional 12,722 shares during the last quarter. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

About Cibus

(Get Free Report)

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.